TCL Archive Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer November 28, 2014
TCL Archive MSKCC Gets $100 Million Commitment From Mortimer Zuckerman For New Research Building. May 12, 2006